ASAnders Jørgen Schou

Anders Jørgen Schou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders Jørgen Schou has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reference serum percentile values of adiponectin, leptin, and adiponectin/leptin ratio in healthy Danish children and adolescents

    by Tine Volquartzen Hamann, Freja Cecilie Barrett Mørk, Andreas Kryger Jensen, Niklas Rye Jørgensen, Malene Søborg Heidemann, Anders Jørgen Schou, Christian Mølgaard, Flemming Pociot, Niels Wedderkopp, Jesper Johannesen

    The adipokines adiponectin and leptin play key roles in human metabolic regulation and have gained great attention as biomarkers for various metabolic pathologies. Though, pediatric reference values are few and needed. This study aims to establish age- and sex-specific adipokine reference percentiles based on healthy Danish school children. Further, it elucidates sex-specific differences in associations between z-scores of examined adipokines and metabolic variables. Serum adiponectin and serum leptin from 853 observations of healthy Danish schoolchildren aged 8–17 years (median 10.0) were quantified by immunoassays. Age- and sex-specific adipokine reference percentiles were calculated cross-sectionally using the LMS method, and adipokine z-scores were calculated from the fitted model. Multiple linear regression models were used to examine sex-specific differences in associations between adipokine z-scores and various metabolic variables. Girls had a higher median value of adiponectin (11.31 vs. 10.65 μg/mL, p < .001) and leptin (2.30 vs. 1.00 ng/mL, p < .001) and a lower median value of adiponectin/leptin ratio (4.64 vs. 10.76, p < .001) compared to boys. Sex-specific differences were found in associations between adiponectin z-score and HDL (p = .010), between leptin z-score and waist circumference z-score (p = .027) and LDL (p = .048), and between adiponectin/leptin ratio z-scores and waist circumference z-score (p = .044) and LDL (p = .040). Reference percentiles of adiponectin, leptin, and adiponectin/leptin ratio are presented in this paper. To our knowledge, this study is the first to demonstrate sex-specific differences in associations between adipokine z-scores and waist circumference z-score and lipids, respectively in healthy children and adolescents.


  • Open Access

    Glycemic control and bone mineral density in children and adolescents with type 1 diabetes

    by Gitte Bjerg Fuusager, Henrik Thybo Christesen, Nikolaj Milandt, Anders Jørgen Schou

    Background/Aim Fracture risk is increased in patients with type 1 diabetes. We aimed to evaluate bone mineral density (BMD) and to identify risk factors associated to lower BMD in Danish children and adolescents with type 1 diabetes. Methods In this cross‐sectional study, BMD and BMD Z‐score were determined by dual‐energy X‐ray absorptiometry (DXA) from a cohort of otherwise healthy children and adolescents with type 1 diabetes. Puberty Tanner stage, HbA1c, disease duration and age at diabetes onset were investigated for associations to DXA results. Results We included 85 patients, 39 girls, 46 boys, with a median (range) age of 13.2 (6‐17) years; disease duration 4.2 (0.4‐15.9) years; HbA1c of the last year 61.8 (41‐106) mmol/mol. Our patients were taller and heavier than the background population. When adjusted for increased height SD and BMI SD, no overall difference in BMD Z‐score was found. When stratified by sex, boys had significantly increased adjusted mean BMD Z‐score, 0.38 (95%CI 0.13;0.62), girls; ‐0.27 (95%CI ‐0.53;0.00). For the whole cohort, a negative correlation between mean latest year HbA1c and BMD Z‐score was found, adjusted ß ‐0.019 (95%CI ‐0.034;‐0.004, p=0.01). Poor glycemic control (HbA1c >58 mmol/mol (7.5%)) within the latest year was likewise negatively correlated with BMD Z‐score, adjusted ß ‐0.35 (95%CI ‐0.69;‐0.014, p=0.04). Conclusion Our study suggests that elevated blood glucose has a negative effect on the bones already before adulthood in patients with type 1 diabetes, although no signs of osteoporosis were identified by DXA.


  • Bone Mass Development in Childhood and Its Association with Physical Activity and Vitamin D Levels. The CHAMPS-Study DK

    by Maria Sode Rønne, Malene Heidemann, Louise Lylloff, Anders J. Schou, Jakob Tarp, Jens Ole Laursen, Niklas Rye Jørgensen, Steffen Husby, Niels Wedderkopp, Christian Mølgaard

    This longitudinal study examined associations of bone mass with physical activity and vitamin D level over more than 6 years through puberty. A total of 663 participants (320 boys) with mean age 9.6 years at baseline (10–17 years at follow-up), underwent dual energy X-ray absorptiometry, anthropometry and blood samples for vitamin D at least twice during the study period (with three possible time-points). Physical activity was assessed using accelerometers at follow-up. A positive association was found between percent time spent at vigorous physical activity and total-body less head bone mineral content (β = 5.8, p = 0.002). The magnitude of this association increased with maturational development; thus physical activity may have a greater influence on bone mass in the more mature participants. The vitamin D levels were also positively associated with bone mass. A high degree of tracking was observed with changes in anthropometric Z scores predictive of deviation from tracking. No environmental factor predicted deviation from tracking.


  • A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β-arrestin–biased signaling

    by Caroline M. Gorvin, Valerie N. Babinsky, Tomas Malinauskas, Peter H. Nissen, Anders J. Schou, Aylin C. Hanyaloglu, Christian Siebold, E. Yvonne Jones, Fadil M. Hannan, Rajesh V. Thakker

    The calcium-sensing receptor (CaSR) is a G protein–coupled receptor (GPCR) that signals through Gq/11 and Gi/o to stimulate cytosolic calcium (Ca2+i) and mitogen-activated protein kinase (MAPK) signaling to control extracellular calcium homeostasis. Studies of loss- and gain-of-function CASR mutations, which cause familial hypocalciuric hypercalcemia type 1 (FHH1) and autosomal dominant hypocalcemia type 1 (ADH1), respectively, have revealed that the CaSR signals in a biased manner. Thus, some mutations associated with FHH1 lead to signaling predominantly through the MAPK pathway, whereas mutations associated with ADH1 preferentially enhance Ca2+i responses. We report a previously unidentified ADH1-associated R680G CaSR mutation, which led to the identification of a CaSR structural motif that mediates biased signaling. Expressing CaSRR680G in HEK 293 cells showed that this mutation increased MAPK signaling without altering Ca2+i responses. Moreover, this gain of function in MAPK activity occurred independently of Gq/11 and Gi/o and was mediated instead by a noncanonical pathway involving β-arrestin proteins. Homology modeling and mutagenesis studies showed that the R680G CaSR mutation selectively enhanced β-arrestin signaling by disrupting a salt bridge formed between Arg680 and Glu767, which are located in CaSR transmembrane domain 3 and extracellular loop 2, respectively. Thus, our results demonstrate CaSR signaling through β-arrestin and the importance of the Arg680-Glu767 salt bridge in mediating signaling bias.


  • Longitudinal evaluation of bone mass, geometry and metabolism in adolescent male athletes. The PRO-BONE study

    by Diana Swolin-Eide, Sverker Hansson, Per Magnusson, Maria Ronne, Malene Heideman, Anders Schou, Jens Ole Laursen, Niels Wedderkopp, Steffen Husby, Christian Molgaard, et al.

  • The Influence of Anthropometry and Body Composition on Children’s Bone Health: The Childhood Health, Activity and Motor Performance School (The CHAMPS) Study, Denmark

    by Malene Heidemann, René Holst, Anders J. Schou, Heidi Klakk, Steffen Husby, Niels Wedderkopp, Christian Mølgaard

    Overweight, physical inactivity and sedentary behaviour have become increasing problems during the past decade. Increased sedentary behaviour may change the body composition (BC) by increasing the fat mass relative to the lean mass (LM). These changes may influence bone health to describe how anthropometry and BC predict the development of the bone accruement. The longitudinal study is a part of The CHAMPS study-DK. Children were DXA scanned at baseline and at 2-year follow-up. BC (LM, BF %) and BMC, BMD and BA were measured. The relationship between bone traits, anthropometry and BC was analysed by multilevel regression analyses. Of the invited children, 742/800 (93 %) accepted to participate. Of these, 682/742 (92 %) participated at follow-up. Mean (range) of age at baseline was 9.5 years (7.7–12.1). Height, BMI, LM and BF % predicted bone mineral accrual and bone size positively and independently. Height and BMI are both positive predictors of bone accruement. LM is a more precise predictor of bone traits than BF % in both genders. The effects of height and BMI and LM on bone accruement are nearly identical in the two genders, while changes in BF % have different but positive effects on bone accretion in both boys and girls.


  • The impact on children's bone health of a school-based physical education program and participation in leisure time sports

    by Malene Heidemann, Eva Jespersen, René Holst, Anders J. Schou, Steffen Husby, Christian Mølgaard, Niels Wedderkopp


  • Open Access

    Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1

    by Jan Frystyk, Anders J Schou, Carsten Heuck, Henrik Vorum, Mikkel Lyngholm, Allan Flyvbjerg, Ole D Wolthers

    Objective: End-point bioassays based on thymidine or sulfate incorporation have demonstrated that glucocorticoid (GC) treatment inhibits serum IGF1 action, but the mechanism is unknown as serum IGF1 concentrations have been reported to either increase or remain unchanged.Aim: To investigate whether GC treatment affects the ability of serum to activate the IGF1 receptor (IGF1R) in vitro (i.e. bioactive IGF1), using a specific cell-based IGF1 kinase receptor activation assay.Subjects and methods: Twenty children with stable asthma (age 7.7–13.8 years) treated for 1 week with 5 mg prednisolone in a randomized, double-blind, placebo-controlled crossover study. Non-fasting serum samples were collected in the afternoon after each 7-day period and assayed for bioactive IGF1, free IGF1, total IGFs, IGF-binding proteins (IGFBPs), and insulin.Results: Prednisolone treatment reduced IGF1 bioactivity by 12.6% from 2.22±0.18 to 1.94±0.15 μg/l (P=0.01) compared with placebo. In contrast, no changes were observed for (μg/l; placebo vs prednisolone) total IGF1 (215±27 vs 212±24), free IGF1 (1.50±0.16 vs 1.43±0.17), total IGF2 (815±26 vs 800±31), IGFBP3 (3140±101 vs 3107±95), IGFBP2 (238±21 vs 220±19), IGFBP1 (32±6 vs 42±10), or IGFBP1-bound IGF1 (24±5 vs 26±7). Insulin remained unchanged as did IGFBP levels as estimated by western ligand blotting. Prednisolone had no direct effects on IGF1R phosphorylation.Conclusions: Our study gives evidence that GC treatment induces a circulating substance that is able to inhibit IGF1R activation in vitro without affecting circulating free or total IGF1. This may be one of the mechanisms by which GC inhibits IGF1 action in vivo. However, the nature of this circulating substance remains to be identified.


    • 9 February 2009
      • Vol. 171  (7) , 534

    [Delayed psychomotor development caused by malignant infantile osteopetrosis].

    by Malene S Heidemann, Anders J Schou, Maria Kibaek, Bendt B Jacobsen

    Malignant infantile osteopetrosis (MIOP) is a hereditary bone disorder caused by osteoclastic dysfunction. Within the first year of life affected children present with recurrent infections, vision impairment, failure to thrive, bone marrow failure, and at later stages neurological deficits and ultimately death. Bone marrow transplant (BMT) is the only curative treatment. We present a patient with MIOP, who showed the first symptoms at three weeks of age, and the disease was diagnosed at 11 months of age. The boy had a successful BMT after which the delayed psychomotor development improved.

  • Bulletin Board

    by André Lacroix, A.B. Grossman, M.O. Savage, M.H. Breuning, Stavroula Christopoulos, Isabelle Bourdeau, I. Mushtaq, J.E. Greening, C.E. Brain, L.A. Perry, et al.